HK Stock Market Move | AKESO(09926) rises by more than 5%, self-developed Gu Mochen antibody obtains NDA acceptance for second indication.

AKESO (09926) rose by more than 5%, rising by 5.16% to HK$118.1 as of the time of publication, with a trading volume of HK$231 million. In terms of news, according to the official WeChat account of AKESO, the company recently announced that its independently developed novel humanized anti-IL-17A monoclonal antibody, gomochi monoclonal antibody (AK111), for the treatment of active ankylosing spondylitis (AS) has submitted a new drug application (sNDA) and has been accepted by the National Medical Products Administration Drug Evaluation Center (NMPA CDE). This marks the potential for this drug to bring new treatment options to nearly 4 million AS patients in China. Gomochi monoclonal antibody is AKESO's third non-tumor blockbuster product to enter the market stage after inusix monoclonal antibody (PCSK9) and eoroki monoclonal antibody (IL-12/IL-23). With inusix monoclonal antibody and eoroki monoclonal antibody successively entering the market and being included in the national medical insurance catalog, gomochi monoclonal antibody, mandoqi monoclonal antibody, and other products are gradually entering the commercialization stage, along with the efficient promotion of non-tumor innovative target drugs such as IL-4R/ST2 dual antibodies, neurodegenerative diseases, targeting multiple indications. The Company's product portfolio is becoming stronger, and the competitiveness of the non-tumor sector is continuing to strengthen.